--- title: "美国食品药品监督管理局批准了 Insmed 公司的肺病药物" description: "美国食品药品监督管理局（FDA）已批准 Insmed 的口服药物 Brinsupri 用于治疗非囊性纤维化支气管扩张症，这标志着该药物成为治疗这种慢性肺病的首个药物。该病在美国影响着 35 万到 50 万名成年人。Brinsupri 通过抑制白血球中的炎症酶，减少由于免疫反应过度活跃而导致的肺部损伤" type: "news" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/252713806.md" published_at: "2025-08-12T15:47:04.000Z" --- # 美国食品药品监督管理局批准了 Insmed 公司的肺病药物 > 美国食品药品监督管理局（FDA）已批准 Insmed 的口服药物 Brinsupri 用于治疗非囊性纤维化支气管扩张症，这标志着该药物成为治疗这种慢性肺病的首个药物。该病在美国影响着 35 万到 50 万名成年人。Brinsupri 通过抑制白血球中的炎症酶，减少由于免疫反应过度活跃而导致的肺部损伤 8 月 12 日（路透社）——美国食品药品监督管理局已批准 Insmed（INSM.O）的一种口服药物用于一种肺病，该公司周二表示，这使其成为治疗这一慢性病的首个药物。 Insmed 的药物品牌名为 Brinsupri，针对非囊性纤维化支气管扩张症，这是一种慢性肺部疾病，其特征是气道永久性损伤，导致持续咳嗽和过量粘液产生。 根据美国肺协会的数据，这种疾病影响美国 35 万到 50 万名成年人。 Brinsupri 通过阻断白血球中的某些炎症酶，防止它们过度活跃并损害肺部。 ### Related Stocks - [INSM.US - Insmed](https://longbridge.com/zh-CN/quote/INSM.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Insmed (NASDAQ:INSM) CEO Sells $3,247,335.00 in Stock | Insmed CEO William Lewis sold 19,215 shares of the company's stock for $3,247,335 on January 12, reducing his ownership | [Link](https://longbridge.com/zh-CN/news/272531097.md) | | Insmed Incorporated Provides Revenue Guidance for the Full Year 2025 | Insmed Incorporated provided revenue guidance for the full year 2025. For the year, the company expected total revenues | [Link](https://longbridge.com/zh-CN/news/272091006.md) | | Insmed Announces Strong 2025 Results and Pipeline Progress | Insmed announced strong preliminary unaudited 2025 financial results, reporting approximately $606.4 million in total re | [Link](https://longbridge.com/zh-CN/news/272077200.md) | | Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference \| INSM Stock News | Insmed Incorporated provided a business update at the 44th Annual J.P. Morgan Healthcare Conference, highlighting unaudi | [Link](https://longbridge.com/zh-CN/news/272071619.md) | | Insmed Maps Aggressive 2026 As Newly Approved Lung Disease Drug Gains Traction, Pipeline Advances | Insmed Inc (INSM) has outlined an aggressive roadmap for 2026, focusing on its respiratory portfolio and upcoming trial | [Link](https://longbridge.com/zh-CN/news/272101100.md) | --- > **免责声明**：本文内容仅供参考，不构成任何投资建议。